PressJanuary 25, 2023 Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25
PressJanuary 25, 2023 Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin
PressJanuary 20, 2023 Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum
PressJanuary 20, 2023 Filament Health Announces Clinical Trial Approval in Partnership With Psychiatric Centre Copenhagen
PressJanuary 20, 2023 Mydecine Innovation Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
PressJanuary 20, 2023 Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
PressJanuary 18, 2023 Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
PressJanuary 18, 2023 FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
PressJanuary 18, 2023 Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements
PressJanuary 18, 2023 Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
PressJanuary 16, 2023 Mindbloom partners with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors
PressJanuary 16, 2023 atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
PressJanuary 12, 2023 Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
PressJanuary 12, 2023 Cybin Inc. Selects Generalized Anxiety Disorder as Target Indication for CYB004
PressJanuary 10, 2023 Irwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical Companies in the US
